Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment. 2003

Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
Department of Nephrology, Medical Faculty, University of Atatürk, Erzurum, Turkey. ramazancetinkaya@yahoo.com

The resistance to erythropoietin, which is used to treat normochromic, normocytic anemia in chronic renal failure, can develop in patients with conditions such as iron deficiency, aluminum toxicity, hyperparathyroidism, chronic inflammatory diseases, and primary hematological disorders. We found amyloidosis in the bone marrow of a woman without any other etiology for erythropoietin resistance who was undergoing chronic hemodialysis. Her anemia did not improve, despite 6 months of erythropoietin therapy. Bone marrow amyloidosis was found to be the reason for erythropoietin-resistant anemia in our patient with chronic renal failure and renal anemia. We present the case of bone marrow amyloidosis because it is a very rare cause of erythropoietin resistance.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D001855 Bone Marrow Diseases Diseases involving the BONE MARROW. Bone Marrow Disease,Disease, Bone Marrow,Diseases, Bone Marrow,Marrow Disease, Bone,Marrow Diseases, Bone
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias

Related Publications

Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
April 2024, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
January 1994, Medicina,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
May 1990, Revista clinica espanola,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
January 2021, Case reports in nephrology and dialysis,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
November 1991, Kidney international,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
January 1990, Acta medica portuguesa,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
December 2003, The Annals of pharmacotherapy,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
January 1990, Acta medica portuguesa,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
August 1996, The New England journal of medicine,
Ramazan Cetinkaya, and Ali Riza Odabas, and Yilmaz Selcuk, and Zekai Erman, and Hasan Kaya
February 2021, Pediatric nephrology (Berlin, Germany),
Copied contents to your clipboard!